Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. PPM Ventures and Triton – acquisition of Pharmacia Diagnostics
Mandate

PPM Ventures and Triton – acquisition of Pharmacia Diagnostics

May 12, 2005

Triton, the European private equity firm, and PPM Ventures Ltd, the private equity business within Prudential Corporation plc, the UK financial services group, has agreed to acquire Pharmacia Diagnostics AB, the Swedish based in-vitro allergy and autoimmune diagnostic testing business of Pfizer Inc, the US-based health care company, for USD 575m.

Vinge acted for Triton and PPM Ventures Ltd.

Johan Cederlund, Christina Kokko (responsible partners)
Sara Mindus (associate)

Related

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026

Vinge advises SEB Kort in connection with a cross-border merger with AirPlus

Vinge advised SEB Kort in connection with a cross-border merger whereby the subsidiary AirPlus has been absorbed into SEB Kort.
August 06, 2026

Vinge advises Altor- and Stena-owned Gunnebo in connection with the divestment of Gunnebo Entrance Control AB to ASSA Abloy

 Vinge has advised Gunnebo in connection with its divestment of Gunnebo Entrance Control AB to ASSA Abloy.
August 04, 2026